JJP Biologics reports positive interim phase 1b data for nebaprubart
3rd June 2026 Uncategorised 0
Early clinical activity supports expansion into broader IgA‑mediated conditions

More: JJP Biologics reports positive interim phase 1b data for nebaprubart
Source: News
